FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation

Circulation

Volumn 100, Issue 12, 1999, Pages 1322-1329

  Hwang, Myung Woo ^a   Matsumori, Akira ^a   Furukawa, Yutaka ^a   Ono, Koh ^a   Okada, Masaharu ^a   Iwasaki, Atsushi ^a   Hara, Masatake ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FTY720; Grafting; Hormones; Immunology; Rejection; Transplantation

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0033592304     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.12.1322     Document Type: Article

References (40)

1. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: eleventh official report, 1994. J Heart Lung Transplant. 1994;13:561-570.
2. Conrad SA, Chhabra A, Vay D. Long-term follow up and complications after cardiac transplantation. J La State Med Soc. 1993;145:217-220,223-225.
3. Oaks TE, Wallwork J. Cardiac transplantation: a review. Br J Biomed Sci. 1993;50:200-211.
4. Yeatman M, Smith JA, Dunning JJ, Large SR, Wallwork J. Cardiac transplantation: a review. Cardiovasc Surg. 1995;3:1-14.
5. Mor F. Cyclosporine. N Engl J Med. 1990;322:1530-1531. Letter.
6. Nair RV, Morris RE. Immunosuppression in cardiac transplantation: a new era in immunopharmacology. Curr Opin Cardiol. 1995;10:207-217.
7. Fyfe AI. Transplant atherosclerosis: the clinical syndrome, pathogenesis and possible model of spontaneous atherosclerosis. Can J Cardiol. 1992; 8:509-519.
8. Lavee J, Kormos RL, Duquensnoy RJ, Zerbe TR, Armitage JM, Vanek M, Hardesty RL, Griffith BP. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant. 1991;10:921-929.
9. Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoe S, Hoshino Y, Chiba K. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200-205.
10. Kahan BD. FTY720: a new immunosuppressive agent with novel mechanism(s) of action. Transplant Proc. 1998;30:2210-2213.
11. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rat, II: FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol. 1998;160:5493-5499.
12. Hirozane T, Matsumori A, Furukawa Y, Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation. 1995;91:386-392.
13. Corry RJ, Winn HJ, Russel PS. Primarily vascularized allografts of heart in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 1973;16:343-350.
14. Furukawa Y, Matsumori A, Hirozane T, Matsui S, Sato Y, Ono K, Sasayama S. Immunomodulation by an adenytate cyclase activator, NKH477, in vivo and vitro. Clin Immunol Immunopathol. 1996;79:25-35.
15. Scott M, Carr D. Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner. J Pharmacol Exp Ther. 1996;278:980-988.
16. Shioi T, Matsumori A, Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 1996;94: 2930-2937.
17. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-2412.
18. Bogdan C, Paik J, Vodovotz Y, Nathan CF. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem. 1992;267:23301-23308.
19. Kroczek RA, Black CD, Barbet J, Shevach EM. Mechanism of action of cyclosporin A in vivo, I: cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens. J Immunol. 1987;139:3597-3603.
20. Batiuk TD, Urmson J, Vincent D, Yatscoff RW, Halloran PF. Quantitating immunosuppression: estimating the 50% inhibitory concentration for in vivo cyclosporine in mice. Transplantation. 1996;61:1618-1624.
21. Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 1978;16:357-360.
22. Swain SL, Bradley LM, Croft M, Tonkonogy S, Atkins G, Weinberg AD, Duncan DD, Hedrick SM, Dutton RW, Huston G. Helper T-cell subset: phenotype, function and the role of lymphokines in regulating their development. Immunol Rev. 1991;123:115-144.
23. Schroeder JS, Gao SZ, Hunt SA, Stinson EB. Accelerated graft coronary artery disease: diagnosis and prevention. J Heart Lung Transplant. 1992; 11:5258-8265.
24. Addonizio LJ, Hsu DT, Douglas JF, Kichuk MR, Michler RE, Quaegebeur JM, Smith CR, Rose EA. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression. Circulation. 1993;88(suppl II):II-224-II-229.
25. Nakagawa T, Sukhova GK, Rabkin E, Winters GL, Schoen FJ, Libby P. Acute rejection accelerates graft coronary disease in transplanted rabbit hearts. Circulation. 1995;92:987-993.
26. Salomon RN, Hughes CC, Shoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Am J Pathol. 1991;138:791-798.
27. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834.
28. Paul LC, Davidoff A, Benediktsson H. Cardiac allograft atherosclerosis in the rat: the effect of histocompatibility factors, cyclosporine, and an angiotensin-converting enzyme inhibitor. Transplantation. 1994;57: 1767-1772.
29. Nagano H, Libby P, Taylor MK, Hasegawa S, Stinn JL, Becker G, Tilney NL, Mitchell RN. Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol. 1998;152:1187-1197.
30. McDouall RM, Batten P, McCormack A, Yacoub MH, Rose ML. MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-gamma and natural killer cells. Transplantation. 1997;64:1175-1180.
31. Raisanen-Sokolowski A, Glysing-Jensen T, Mottram PL, Russell ME. Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allograft. Arterioscler Thromb Vasc Biol. 1997;17:2115-2122.
32. Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy. 1996;8:243-249.
33. Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, Wyner LR, Karnovsky MJ. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation rat model of chronic rejection. Transplantation. 1995;59:572-578.
34. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol. 1992;149:2709-2714.
35. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willett TA, Sayegh MH. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest. 1996;97:833-838.
36. Orosz CG, Ohye RG, Pelletier RP, Van Buskirk AM, Huang E, Morgan C, Kincade PW, Ferguson RM. Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation. 1993;56:453-460.
37. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992;255:1125-1127.
38. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation. 1995;92:450-456.
39. Nagano H, Mitchel RN, Taylor MK, Hasegawa S, Nicholas N, Libby P. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997;100:550-557.
40. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts, III: effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplantation. 1994;57: 1367-1371.